Tüberküloz Dışı Mikobakteri Enfeksiyonlarında Kullanılan İlaçlar: Etki ve Direnç Mekanizmaları
Referanslar
Alkan Bilik Ö, Özcan N, Selimoğlu Şen H, et al. Species diversity and clinical relevance of nontuberculous mycobacterium isolated from pulmonary and extrapulmonary samples in southeastern Turkey, 2014 to 2023: A retrospective cross-sectional study. Medicine (Baltimore). 2025;104(29): e43415. doi:10.1097/md.0000000000043415
To K, Cao R, Yegiazaryan A, et al. General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus. J Clin Med. 2020;9(8): 2541. doi:10.3390/jcm9082541
Saxena S, Spaink HP, Forn-Cuní G. Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models. Biology (Basel). 2021;10(2): 96 doi:10.3390/biology10020096
Rindi L. Efflux Pump Inhibitors Against Nontuberculous Mycobacteria. Int J Mol Sci. 2020;21(12): 4191 doi:10.3390/ijms21124191
Nguyen MH, Haas MK, Kasperbauer SH, et al. Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clin Infect Dis. 2024;79(4): e27-e47. doi:10.1093/cid/ciae421
Pennington KM, Vu A, Challener D, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis. 2021;24: 100244. doi:10.1016/j.jctube.2021.100244
Tarashi S, Siadat SD, Fateh A. Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead. Biomed Res Int. 2022;2022: 8168750. doi:10.1155/2022/8168750
Brown-Elliott BA, Woods GL. Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria. J Clin Microbiol. 2019;57(10): e00834-19. doi:10.1128/jcm.00834-19
Wu ML, Aziz DB, Dartois V, et al. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8): 1502-19. doi:10.1016/j.drudis.2018.04.001
Bhanushali J, Jadhav U, Ghewade B, et al. Unveiling the Clinical Diversity in Nontuberculous Mycobacteria (NTM) Infections: A Comprehensive Review. Cureus. 2023;15(11): e48270. doi:10.7759/cureus.48270
Cimino C, Rivera CG, Pearson JC, et al. Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians. Open Forum Infect Dis. 2024;11(4): ofae128. doi:10.1093/ofid/ofae128
Tursun EG, Bozok T, Aslan G. Antimicrobial resistance mechanisms in non-tuberculous mycobacteria. Folia Microbiol (Praha). 2025;70(4): 729-38. doi:10.1007/s12223-025-01287-z
Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020;71(4): 905-13. doi:10.1093/cid/ciaa1125
Tunesi S, Zelazny A, Awad Z, et al. Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections. Clin Microbiol Infect. 2024;30(6): 718-25. doi:10.1016/j.cmi.2023.09.019
Fröberg G, Maurer FP, Chryssanthou E, et al. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution. Clin Microbiol Infect. 2023;29(6): 758-64. doi:10.1016/j.cmi.2023.02.007
Tagliani E, Kohl TA, Ghodousi A, et al. Appeal from the European tuberculosis reference laboratory network (ERLTB-Net) for improving the diagnosis of infections due to nontuberculous mycobacteria. Clin Microbiol Infect. 2024;30(1): 4-6. doi:10.1016/j.cmi.2023.06.005
Faria S, Joao I, Jordao L. General Overview on Nontuberculous Mycobacteria, Biofilms, and Human Infection. J Pathog. 2015;2015: 809014. doi:10.1155/2015/809014
Nguyen TQ, Heo BE, Jeon S, et al. Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches. Front Microbiol. 2024;15: 1331508. doi:10.3389/fmicb.2024.1331508
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4): 367-416. doi:10.1164/rccm.200604-571ST
Esteban J, García-Coca M. Mycobacterium Biofilms. Front Microbiol. 2017;8: 2651. doi:10.3389/fmicb.2017.02651
Wang M, Khan MT, Yang Z, et al. Clinical Characteristics of Nontuberculous Mycobacterial Positivity Occurring During Multidrug-Resistant Tuberculosis Treatment: A Retrospective Study. Trop Med Infect Dis. 2025;10(3): 83. doi:10.3390/tropicalmed10030083
Koh WJ. Nontuberculous Mycobacteria-Overview. Microbiol Spectr. 2017;5(1): 10.1128 doi:10.1128/microbiolspec.TNMI7-0024-2016
Haworth CS, Banks J, Capstick T, et al. British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res. 2017;4(1): e000242. doi:10.1136/bmjresp-2017-000242
Kumar K, Ponnuswamy A, Capstick TG, et al. Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management. Clin Med (Lond). 2024;24(1): 100017. doi:10.1016/j.clinme.2024.100017
Wamalwa R, Guyah B, Shaviya N. Antibiotic resistance in Mycobacterium tuberculosis and non-tuberculous Mycobacteria. African Journal of Empirical Research. 2024;5(4): 1001–10. doi:10.51867/ajernet.5.4.83
Nasiri MJ, Haeili M, Ghazi M, et al. New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Front Microbiol. 2017;8: 681. doi:10.3389/fmicb.2017.00681
Pereira AC, Ramos B, Reis AC, et al. Non-Tuberculous Mycobacteria: Molecular and Physiological Bases of Virulence and Adaptation to Ecological Niches. Microorganisms. 2020;8(9): 1380. doi:10.3390/microorganisms8091380
Patrick R. Murray KSR, Michael A. Pfaller. Medical Microbiology. Philadelphia: Elsevier; 2020.
Vázquez-Laslop N, Mankin AS. How Macrolide Antibiotics Work. Trends Biochem Sci. 2018;43(9): 668-84. doi:10.1016/j.tibs.2018.06.011
Huang WC, Yu MC, Huang YW. Identification and drug susceptibility testing for nontuberculous mycobacteria. J Formos Med Assoc. 2020;119: 32-41 doi:10.1016/j.jfma.2020.05.002
Tursun EG, Bozok T, Biçmen C, et al. Evaluation of the interaction and synergy potential of bedaquiline and clarithromycin in combination with efflux pump inhibitors in clinical isolates of Mycobacterium abscessus complex. Folia Microbiol (Praha). 2025. doi:10.1007/s12223-025-01357-2
Luthra S, Rominski A, Sander P. The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance. Front Microbiol. 2018;9: 2179. doi:10.3389/fmicb.2018.02179
Johansen MD, Herrmann J-L, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nature Reviews Microbiology. 2020;18(7): 392-407. doi:10.1038/s41579-020-0331-1
Victoria L, Gupta A, Gómez JL, et al. Mycobacterium abscessus complex: A Review of Recent Developments in an Emerging Pathogen. Front Cell Infect Microbiol. 2021;11: 659997. doi:10.3389/fcimb.2021.659997
Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25(3): 545-82. doi:10.1128/cmr.05030-11
Rizzo AR, Moniri NH. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use. BMC Infectious Diseases. 2022;22(1): 874. doi: 10.1186/s12879-022-07857-7
Rudra P, Hurst-Hess K, Lappierre P, et al. High Levels of Intrinsic Tetracycline Resistance in Mycobacterium abscessus Are Conferred by a Tetracycline-Modifying Monooxygenase. Antimicrob Agents Chemother. 2018;62(6): e00119-18. doi:10.1128/aac.00119-18
Terschlüsen E, Aono A, Anastasiou DM, et al. In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates. Diagn Microbiol Infect Dis. 2025;111(3): 116663. doi:10.1016/j.diagmicrobio.2024.116663
Schäfle D, Selchow P, Borer B, et al. Rifabutin Is Inactivated by Mycobacterium abscessus Arr. Antimicrob Agents Chemother. 2021;65(3): e02215-20. doi:10.1128/aac.02215-20
Xiang X, Gong Z, Deng W, et al. Mycobacterial ethambutol responsive genes and implications in antibiotics resistance. J Drug Target. 2021;29(3): 284-93. doi:10.1080/1061186x.2020.1853733
Huh HJ, Kim SY, Jhun BW, et al. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infect Genet Evol. 2019;72: 169-82. doi:10.1016/j.meegid.2018.10.003
Louw GE, Warren RM, Gey van Pittius NC, et al. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother. 2009;53(8): 3181-9. doi:10.1128/aac.01577-08
Song L, Wu X. Development of efflux pump inhibitors in antituberculosis therapy. Int J Antimicrob Agents. 2016;47(6): 421-9. doi:10.1016/j.ijantimicag.2016.04.007
Laws M, Jin P, Rahman KM. Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance. Trends Microbiol. 2022;30(1): 57-68. doi:10.1016/j.tim.2021.05.001
van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012;15(3): 149-61. doi:10.1016/j.drup.2012.04.001
Danilchanka O, Pavlenok M, Niederweis M. Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrob Agents Chemother. 2008;52(9): 3127-34. doi:10.1128/aac.00239-08
Khoshnood S, Taki E, Sadeghifard N, et al. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis. Front Microbiol. 2021;12: 717045. doi:10.3389/fmicb.2021.717045
Story-Roller E, Maggioncalda EC, Cohen KA, et al. Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities. Front Microbiol. 2018;9: 2273. doi:10.3389/fmicb.2018.02273
Liu Y, Liu T, Xiao K, et al. Effects of Oral Versus Intravenous Linezolid Administration on Treatment Effect and Incidence of Thrombocytopenia in Patients with Severe Infection. Intensive Care Research. 2024;4(3): 171-9. doi: 10.1007/s44231-024-00071-w
Cocorullo M, Bettoni C, Foiadelli S, et al. Moles of molecules against Mycobacterium abscessus: A review of current research. Future Pharmacology. 2023;3(3): 637-63. doi:10.3390/futurepharmacol3030041
Deshkar AT, Shirure PA. Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis. Cureus. 2022;14(8): e28519. doi:10.7759/cureus.28519